Jia-Cheng Yang1,2, Eric Risch3, Meiqin Zhang4, Chan Huang5, Huatian Huang6, Lingeng Lu3. 1. School of Electric & Information Engineering, Lanzhou Jiaotong University, Lanzhou 730070, China. 2. Gansu Provincial Cancer Hospital, Lanzhou 730050, China. 3. Department of Chronic Disease Epidemiology, School of Public Health, School of Medicine, Yale Cancer Center, Yale University, 60 College Street, New Haven, CT 06520-8034, USA. 4. Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. 5. School of Basic Medical Science & Nursing, Chengdu University, Chengdu 610106, China. 6. Guizhou Qianxinan People's Hospital, Xingyi 652400, China.
Abstract
AIM: To investigate the association between NSUN2/IGF-II signature and ovarian cancer survival. METHODS: Using a publicly accessible dataset of RNA sequencing and clinical follow-up data, we performed Classification and Regression Tree and survival analyses. RESULTS: Patients with NSUN2 high IGF-II low had significantly superior overall and disease progression-free survival, followed by NSUN2 low IGF-II low, NSUN2 high IGF-II high and NSUN2 low IGF-II high (p < 0.0001 for overall, p = 0.0024 for progression-free survival, respectively). The associations of NSUN2/IGF-II signature with the risks of death and relapse remained significant in multivariate Cox regression models. Random-effects meta-analyses show the upregulated NSUN2 and IGF-II expression in ovarian cancer versus normal tissues. CONCLUSION: The NSUN2/IGF-II signature associates with heterogeneous outcome and may have clinical implications in managing ovarian cancer.
AIM: To investigate the association between NSUN2/IGF-II signature and ovarian cancer survival. METHODS: Using a publicly accessible dataset of RNA sequencing and clinical follow-up data, we performed Classification and Regression Tree and survival analyses. RESULTS:Patients with NSUN2 high IGF-II low had significantly superior overall and disease progression-free survival, followed by NSUN2 low IGF-II low, NSUN2 high IGF-II high and NSUN2 low IGF-II high (p < 0.0001 for overall, p = 0.0024 for progression-free survival, respectively). The associations of NSUN2/IGF-II signature with the risks of death and relapse remained significant in multivariate Cox regression models. Random-effects meta-analyses show the upregulated NSUN2 and IGF-II expression in ovarian cancer versus normal tissues. CONCLUSION: The NSUN2/IGF-II signature associates with heterogeneous outcome and may have clinical implications in managing ovarian cancer.